BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

Core Insights - BriaCell Therapeutics Corp. has confirmed the complete resolution of lung metastasis in a patient with metastatic breast cancer after treatment with its Bria-OTS immunotherapy, marking a significant milestone in the ongoing Phase 1/2a study [1][6][8] Group 1: Treatment Efficacy - The Bria-OTS monotherapy resulted in a 100% resolution of lung tumors in a 78-year-old female patient after two months of therapy, with confirmation of this resolution at the four-month follow-up [2][5] - The patient had extensive metastases prior to treatment and showed stable disease in other areas after receiving Bria-OTS injections [5][6] - The treatment was well-tolerated, and the patient remains in the study with stable disease elsewhere [6][8] Group 2: Study Details - Bria-OTS is currently being investigated in a Phase 1/2a dose escalation study for metastatic recurrent breast cancer, with a focus on safety and efficacy as a monotherapy [9] - This study represents a next-generation advancement of BriaCell's lead candidate, Bria-IMT™, which is in a pivotal Phase 3 study for metastatic breast cancer [9] Group 3: Industry Context - The results from the Bria-OTS study are particularly significant given the limited treatment options available for patients with hormone receptor-positive metastatic breast cancer, despite advancements in antibody-drug conjugates and immune checkpoint inhibitors [8] - The initial data from the Bria-OTS study demonstrates promising anti-tumor activity, providing early validation for BriaCell's personalized immunotherapy approach [8][9]